Becker's Healthcare December 20, 2024
Rylee Wilson

Medicaid could spend $29.9 billion on drugs to treat type 2 diabetes and weight loss, according to a report from HHS’ Office of Inspector General.

The report, published Dec. 19, reviewed Medicaid program spending for 10 GLP-1 and SGLT-2 drugs to treat type 2 diabetes between 2019 and 2023. The report also tracked Medicaid spending for Wegovy and Saxenda, two GLP-1 drugs approved for weight loss.

GLP-1 drugs, including Ozempic, Monjauro and Rybelsus, treat type 2 diabetes. The drugs can cost more than $1,000 a month SGLT-2 drugs include Jardiance, Farxiga and Invokana.

Here are five numbers to know from the report:

  1. Between 2019 and 2023, Medicaid spending on 12 diabetes and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Insurance, Medicaid, Pharma / Biotech, Survey / Study, Trends
Related Articles:
CMS Launches New Program for Mental Health, OUD Treatment
Georgia Medicaid shakeup could force 3 in 4 beneficiaries to change plans: Centene CEO
CMS Announces Participating States in The Innovation in Behavioral Health Model
Hospital Margins Rebounded in 2023, But Rural Hospitals and Those With High Medicaid Shares Were Struggling More Than Others
Proposed Rule Would Expand Medicare And Medicaid Coverage For Anti-Obesity Medications

Share This Article